Notably, miR-503 has been shown to regulate pancreatic β-cell activity by targeting the mTOR pathway, implying that targeting the miR-503/mTOR axis could be a promising therapeutic strategy for GDM [90]. This evidence concerns the gene MTOR and gestational diabetes.